ClinicalTrials.gg
Active, not recruitingNCT07486050Updated Mar 25, 2026

The Impact of Social Worker Referrals on Diabetes and Loneliness

An interventional study of Social worker referral to address loneliness and Continue Primary care in Diabete Mellitus and Loneliness, sponsored by University of Toronto. Active, not recruiting at 1 site in Canada. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by University of Toronto · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Diabetes Mellitus by University of Toronto — 2 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus · University of Toronto.

Planned enrollment
5th of 24
90 · median 32
Started
2026
the only one that year
No phase
20 of 41
2 open now
Registered
41st of 41
by date

Among the 41 studies in Diabetes Mellitus by University of Toronto, this one is the 5th largest by planned enrollment of the 24 interventional ones that give a count, is the only one that started in 2026, is one of 20 with no phase, and was the 41st registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

2 of the 41 studies in Diabetes Mellitus by University of Toronto are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Diabetes Mellitus by University of Toronto, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if referral to a social worker (social prescribing) can help reduce loneliness and improve blood sugar control (A1C) in older adults with diabetes. It will also help us understand how this approach can support overall well-being in seniors.

The main questions it aims to answer are:

  • Does referral to a social worker reduce feelings of loneliness in older adults with diabetes?
  • Does this support improve blood sugar control (A1C)?

Researchers will compare social worker referral to usual diabetes care to see if this approach improves both social well-being and diabetes outcomes.

Participants will:

  • Be assigned (like flipping a coin) to either meet with a social worker or continue their usual care
  • Complete a short 3-question loneliness survey at the start and again after 6 months
  • Have their A1C levels reviewed from their routine medical records
Read the detailed description

This study is a pragmatic, single-centre, parallel-group randomized controlled trial evaluating the integration of social prescribing into primary care for older adults with diabetes who experience loneliness. The intervention is delivered within an academic family health team and leverages existing interprofessional resources to address social determinants of health as part of routine clinical care.

Potential participants will be identified through electronic medical record (EMR) queries and clinic-based outreach. Loneliness screening will be conducted using the three-item UCLA Loneliness Scale (UCLA-3), administered via a secure electronic platform (REDCap). A flexible consent process, including both electronic and verbal options, will be used to accommodate varying levels of digital literacy within the target population.

Following enrolment, participants will be assigned to study arms using simple randomization (coin toss). The intervention consists of a structured referral to a primary care social worker. The social worker will conduct an initial assessment of the participant's social context, including social supports, barriers to engagement, and unmet practical needs. Based on this assessment, a co-developed plan will be implemented, which may include connection to community resources, facilitation of social engagement activities, and support addressing social or logistical barriers. Follow-up will be individualized in frequency and modality (in-person or virtual), reflecting a pragmatic, patient-centred approach.

Intervention delivery will not be protocolized beyond core components, in order to reflect real-world clinical practice. All social worker interactions will be documented within the EMR, allowing for characterization of intervention exposure (e.g., number and type of contacts). Participants in the comparator arm will continue to receive usual diabetes care during the study period, with access to social worker referral after study completion.

Study data will be collected through a combination of participant-reported measures and EMR-derived clinical data. Data will be stored in REDCap using unique study identifiers, with linkage files maintained separately on secure, access-restricted servers. Analyses will use regression-based approaches to estimate between-group differences, adjusting for baseline values and relevant covariates.

This study is designed to evaluate the feasibility and effectiveness of incorporating social care into chronic disease management within primary care settings. Findings will inform the scalability and implementation of social prescribing interventions aimed at reducing loneliness and improving health outcomes among older adults.

03

Conditions studied

  • Diabete Mellitus
  • Loneliness

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diabetes, lonely

Exclusion criteria

Exclusion Criteria:

  • Dementia, acute psychiatric or medical illness
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Continue primary care

    Continue seeing primary care provider

    Other: Continue Primary care

  • Experimental
    Intervention arm

    Referral to see a social worker

    Behavioral: Social worker referral to address loneliness

Interventions

  • BehavioralSocial worker referral to address loneliness

    Patients will be referred to social worker for loneliness management

  • OtherContinue Primary care

    Continue seeing primary care

06

What researchers measure

Primary outcomes

  1. Hemoglobin A1C (glycated hemoglobin) level

    Hemoglobin A1C (glycated hemoglobin) is a routinely used laboratory measure that reflects average blood glucose levels over the preceding 3 months. In this study, A1C values will be obtained from participants' electronic medical records (EMR) as part of routine clinical care; no additional blood draws will be required for research purposes. Baseline A1C will be defined as the most recent value within ±4 weeks of enrolment. Follow-up A1C will be the value obtained closest to 6 months after enrolment, within routine clinical testing intervals. A1C is reported as a percentage (%), with higher values indicating poorer glycemic control. Change in A1C from baseline to 6 months will be used to assess the effect of the intervention on glycemic control. The secondary analysis will adjust for baseline A1C and relevant clinical factors, including medication changes where applicable.

    Time frame: 6 months

Secondary outcomes

  1. The University of California, Los Angeles (UCLA - 3) score

    The UCLA 3-item Loneliness Scale (UCLA-3) is a validated, brief self-reported measure used to assess subjective feelings of loneliness and social isolation. It consists of three questions that ask participants how often they experience key aspects of loneliness: (1) lacking companionship, (2) feeling left out, and (3) feeling isolated from others. Each item is scored on a 3-point Likert scale: 1. = Hardly ever 2. = Some of the time 3. = Often The total score ranges from 3 to 9, with higher scores indicating greater perceived loneliness. In this study, the UCLA-3 is administered at baseline and at 6 months electronically via REDCap. A score of ≥5 is used as the threshold to define clinically relevant loneliness for study eligibility. Change in UCLA-3 score over time is used to assess the effect of the intervention, with a reduction in score indicating improvement in perceived loneliness.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Publications

  • Ida S, Murata K. Social Isolation of Older Adults With Diabetes. Gerontol Geriatr Med. 2022 Aug 2;8:23337214221116232. doi: 10.1177/23337214221116232. eCollection 2022 Jan-Dec. PubMed 35937276 ↗
  • Cho E, Kim J, Bang S. Loneliness in older adults with diabetes mellitus: a scoping review. Psychol Health Med. 2024 Sep;29(8):1548-1563. doi: 10.1080/13548506.2023.2299665. Epub 2024 Jan 5. PubMed 38179980 ↗
  • Song Y, Zhu C, Shi B, Song C, Cui K, Chang Z, Gao G, Jia L, Fu R, Dong Q, Feng L, Zhu C, Yin D, Manson JE, Dou K. Social isolation, loneliness, and incident type 2 diabetes mellitus: results from two large prospective cohorts in Europe and East Asia and Mendelian randomization. EClinicalMedicine. 2023 Sep 21;64:102236. doi: 10.1016/j.eclinm.2023.102236. eCollection 2023 Oct. PubMed 37767193 ↗
  • Henriksen RE, Nilsen RM, Strandberg RB. Loneliness increases the risk of type 2 diabetes: a 20 year follow-up - results from the HUNT study. Diabetologia. 2023 Jan;66(1):82-92. doi: 10.1007/s00125-022-05791-6. Epub 2022 Sep 28. PubMed 36168066 ↗
  • Kobos E, Szewczyk A, Swiatkowska T, Kryczka T, Sienkiewicz Z. Relationship between loneliness and blood glucose control in diabetes. BMC Public Health. 2020 Jul 20;20(1):1140. doi: 10.1186/s12889-020-09241-z. PubMed 32689971 ↗

Individual participant data

Plan to share: No — As per research ethic board policy, only result of the study will be disseminated.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Dec 2026, 11 months after the start.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 11 months is below that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2026
First posted
Mar 20, 2026
StartActual
Jan 1, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07486050
Responsible party
Nkechi Ikeaba (Resident Physician, University of Toronto) — Principal investigator
First posted
Mar 20, 2026
Start date
Jan 1, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Mar 25, 2026

Study contacts

Rachel Walsh, MD CCFP
principal investigator · Sunnybrook Health Sciences Centre

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion